Effect of Docetaxel Combined with Cisplatin Preoperative Neoadjuvant Chemotherapy for Stage III NSCLC.
The aim of this study was to investigate the effect of docetaxel plus cisplatin preoperative neoadjuvant chemotherapy in stage III non-small cell lung cancer (NSCLC). It was an analytical study carried out from May 2013 to May 2017. Eightytwo patients with stage III NSCLC were divided into Group A and B according to a random number table (n=41). Group A received neoadjuvant chemotherapy with docetaxel plus cisplatin before surgery. Group B underwent surgical treatment after preoperative examination. Compared with group B,operation time of group A was shorter (p<0.001); intraoperative blood loss of group A was lower (p<0.001); surgical resection rate and 1-year survival rate in group A were higher (p=0.013, 0.023). This suggested that preoperative neoadjuvant chemotherapy with docetaxel plus cisplatin may improve surgical resection rate, shorten operation time, reduce intraoperative blood loss, and prolong survival of patients.